InvestSMART

Zelira Therapeutics Limited (ASX: ZLD) - Announcements

- Current share price for ZLD : $0.500

ASX company news and announcements for Zelira Therapeutics Limited (ZLD) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Zelira Therapeutics Limited (ZLD) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Zelira Therapeutics Limited (ZLD), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Zelira Therapeutics Limited (ZLD)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$7 Change of Company Address 27 Apr 2021 11:20AM $0.060 $0.500 risen by 733.33%
$7 March 2021 Quarterly Report 21 Apr 2021 10:01AM $0.060 $0.500 risen by 733.33%
$7 Appendix 4C - quarterly 21 Apr 2021 9:58AM $0.060 $0.500 risen by 733.33%
$7 Zelira Announces Record Third Quarter Revenue 15 Apr 2021 8:21AM $0.062 $0.500 risen by 706.45%
$7 Cleansing Notice and Appendix 2A 23 Feb 2021 5:36PM $0.078 $0.500 risen by 541.03%
$7 Appendix 4D & FY21 Interim Financial Report 22 Feb 2021 3:23PM $0.076 $0.500 risen by 557.89%
$7 Strategic Transition and Executive Changes 15 Feb 2021 8:13AM $0.084 $0.500 risen by 495.24%
$7 US National Cannabis Roundtable appoints Zelira as Director 11 Feb 2021 9:45AM $0.085 $0.500 risen by 488.24%
$7 Appendix 4C - quarterly 29 Jan 2021 9:20AM $0.095 $0.500 risen by 426.32%
$7 December 2020 Quarterly Report 29 Jan 2021 9:19AM $0.095 $0.500 risen by 426.32%
$7 Appendix 3G 20 Jan 2021 7:08PM $0.097 $0.500 risen by 415.46%
$7 Issue of Unquoted Options 20 Jan 2021 7:00PM $0.097 $0.500 risen by 415.46%
$7 Clarification regarding HOPE Distribution to Washington DC 18 Dec 2020 5:29PM $0.096 $0.500 risen by 420.83%
$7 Zelira Expands HOPE Distribution to Washington DC, USA 14 Dec 2020 8:22AM $0.099 $0.500 risen by 405.05%
$7 Change of Director's Interest Notice 11 Dec 2020 4:40PM $0.099 $0.500 risen by 405.05%
$7 R&D Tax Incentive Refund 11 Dec 2020 8:20AM $0.100 $0.500 risen by 400%
$7 ZLD Partners with SprinJene to Launch CBD Toothpaste in US 2 Dec 2020 8:17AM $0.081 $0.500 risen by 517.28%
$7 Cancellation of Unlisted Options 20 Nov 2020 6:01PM $0.068 $0.500 risen by 635.29%
$7 Appendix 3G 13 Nov 2020 5:59PM $0.073 $0.500 risen by 584.93%
$7 Results of Meeting 13 Nov 2020 1:51PM $0.070 $0.500 risen by 614.29%
$7 EMD:Emyria Enters Data Deal with ZLD to Support Autism Trial 9 Nov 2020 9:30AM $0.072 $0.500 risen by 594.44%
$7 Emyria Deal and Autism Observational Trial for HOPE Products 9 Nov 2020 8:19AM $0.072 $0.500 risen by 594.44%
$7 Appendix 4C - quarterly 30 Oct 2020 8:28AM $0.076 $0.500 risen by 557.89%
$7 September 2020 Quarterly Report 30 Oct 2020 8:28AM $0.076 $0.500 risen by 557.89%
$7 HOPE launches in Australia after TGA approves release 27 Oct 2020 8:14AM $0.079 $0.500 risen by 532.91%

251 - 275 of 547 results

Page 11 of 22

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.